TICKERNERD
Menu
KRMDKRMDHealthcare · Medical Instruments & Supplies

KRMD Stock Forecast: KORU Medical Systems, Inc. Price Predictions for 2026-2027

Last close, 25 Aug 2026
$3.21
−0.31% on the day

The 5 Wall Street analysts covering KORU Medical Systems, Inc. hold a median 12-month price target of $6 — +86.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 24 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$147.4M
Ticker Nerd rank
96 / 100
Median analyst target
$6.00
Analysts covering
5
Revenue$12.0M+18.2% y/y
Operating income$627K
Net income$252K
Free cash flow−$361K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.6%
1M
−16.2%
YTD
−44.8%
1Y
−23.6%
From 52W high
−50.8%
From 52W low
0.0%
$3.21
$6.52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KRMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores KORU Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Issuance
81
Growth
79
Volatility
74
Value
72
Size
71
Accruals
70
Revisions
65
Momentum
45

Quality (91): The business earns solid, repeatable profits on what it owns.

Momentum (45): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KRMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KRMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00Oct 25Jan 26Apr 26Jul 26KRMDHigh $8.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $5.00Median $6.00High $8.00

The green dot is the last close — the median target sits +86.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Mar 2026B. Riley SecuritiesMaintainsBuy$7.00 → $8.00
13 Mar 2026Canaccord GenuityMaintainsBuy$6.00
22 Dec 2025Lake StreetMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
7 Aug 2025Piper SandlerMaintainsNeutral—
8 May 2025Piper SandlerMaintainsNeutral—
14 Feb 2025Piper SandlerDowngradeNeutral—
17 Jan 2025Craig-HallumMaintainsBuy—
14 Jan 2025Lake StreetMaintainsBuy—
14 Nov 2024Canaccord GenuityMaintainsBuy—
14 Nov 2024Craig-HallumMaintainsBuy—
14 Nov 2024Piper SandlerMaintainsOverweight—
8 Aug 2024Piper SandlerMaintainsOverweight—
14 Mar 2024B. Riley SecuritiesReiteratesBuy—
7 Dec 2023Canaccord GenuityReiteratesBuy—
7 Sept 2023B. Riley SecuritiesInitiatesBuy—
7 Sept 2023Lake StreetInitiatesBuy—
3 Aug 2023Piper SandlerMaintainsOverweight—
6 Jan 2023Piper SandlerMaintainsOverweight—
10 Nov 2022Canaccord GenuityUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KRMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 25 Aug 2026, KORU Medical Systems, Inc. returned −23.6% against +20.5% for the S&P 500, dividends included.

KRMD vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26KRMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KRMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−125.0%
Analysts raising
0
Analysts cutting
0
Fundamentals

KORU Medical Systems, Inc. (KRMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−53.5×

Cheaper than 98% of US stocks

Price / sales
3.3×

Cheaper than 39% of US stocks

Price / book
8.2×

Cheaper than 13% of US stocks

EV / EBITDA
−146.2×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
18.2%

Higher than 67% of US stocks

Earnings growth (YoY)
18.2%

Higher than 57% of US stocks

Gross margin
65.1%

Higher than 79% of US stocks

Operating margin
5.2%

Higher than 55% of US stocks

Net margin
−4.0%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−10.5%

Higher than 35% of US stocks

Return on assets
−3.9%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

KORU Medical Systems, Inc. (KRMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • KORU Medical Systems, Inc. has a market value of $147.4M and an enterprise value of $143.2M.

  • Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter grew 18.2% year on year.

  • Net income over the same four quarters: −$1.8M, a −4.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $243K.

  • Shares outstanding: 46.1M.

  • Trailing P/E: −53.5×; forward P/E: 91.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • KORU Medical Systems, Inc. employs 73 people — $618K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

KRMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
KRMDKORU Medical Systems, Inc.$147.4M
96
STXSStereotaxis, Inc.$138.1M
29
PDEXPro-Dex, Inc.$213.5M
85
UTMDUtah Medical Products, Inc.$228.0M
78
OSUROraSure Technologies, Inc.$264.1M
88
EMBCEmbecta Corp.$295.5M
85
SMTISanara MedTech, Inc.$306.1M
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own KORU Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KRMD news & analysis

KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published a transcript of KORU Medical Systems, Inc.'s Q2 2026 earnings call. The transcript covers the company's quarterly earnings discussion for the second quarter of fiscal year 2026.

Why it matters — A KRMD watcher would care because the earnings call transcript provides detailed commentary from management on the company's latest quarterly results, which is a key source for assessing recent performance.

KORU Medical Systems Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

KORU Medical Systems reported second-quarter revenue of $12 million, up 18% year over year, supported by domestic patient starts, market-share gains, and international demand. The company posted its first positive net income since 2019, raised its full-year gross-margin outlook, and narrowed revenue guidance because certain international prefilled-syringe market launches are taking longer than expected.

Why it matters — For KRMD watchers, the quarter marks a profitability milestone and improved margin outlook while also signalling a more cautious revenue forecast tied to slower international launch timing.

KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates

Zacks Investment Research · 5 Aug 2026positive

KORU Medical Systems reported Q2 earnings of $0.01 per share, beating the Zacks Consensus Estimate of a $0.02 per share loss. This compares with break-even earnings per share in the same quarter a year ago.

Why it matters — The earnings beat over consensus estimates marks a favorable quarterly result for KRMD watchers, as the company turned a profit relative to the expected loss.

KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance

Business Wire · 5 Aug 2026positive

KORU Medical Systems announced its financial results for the second quarter ended June 30, 2026 and updated its full year 2026 guidance. The company reported that net revenues grew 18% over the prior period.

Why it matters — KRMD watchers would care because the results and updated full-year guidance offer the latest signal on the company's revenue growth trajectory in its large volume subcutaneous infusion market.

KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference

Business Wire · 29 July 2026neutral

KORU Medical Systems announced that its management team will participate in and present at the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026.

Why it matters — Conference participation gives KORU Medical an opportunity to present its business and large-volume subcutaneous infusion technology to the investment community.

FAQ

Frequently asked questions about KRMD stock

What is the KRMD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering KORU Medical Systems, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KRMD stock a buy right now?

Of the 5 analysts covering KORU Medical Systems, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks KORU Medical Systems, Inc. 96 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KRMD?

As at 24 Aug 2026, KORU Medical Systems, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will KRMD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +86.9% from the last close, and Ticker Nerd's factor model ranks KORU Medical Systems, Inc. 96 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KRMD stock forecast for 2030?

No analyst covering KORU Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has KRMD stock performed over the past year?

KORU Medical Systems, Inc. returned -23.6% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does KORU Medical Systems, Inc. do?

KORU Medical Systems Inc. is a medical technology company that develops, manufactures, and commercializes subcutaneous infusion solutions for patients who require ongoing drug delivery.

What is the latest news on KRMD?

The most recent item we track (Seeking Alpha, 6 Aug 2026): "KORU Medical Systems, Inc. (KRMD) Q2 2026 Earnings Call Transcript". Seeking Alpha published a transcript of KORU Medical Systems, Inc.'s Q2 2026 earnings call. The transcript covers the company's quarterly earnings discussion for the second quarter of fiscal year 2026.

Company

About KORU Medical Systems, Inc.

KORU Medical Systems Inc. is a medical technology company that develops, manufactures, and commercializes subcutaneous infusion solutions for patients who require ongoing drug delivery. KORU Medical Systems Inc. focuses on home and specialty infusion care, with products designed to support the administration of therapies for chronic and complex conditions. Its portfolio includes the FREEDOM infusion systems, syringe drivers, subcutaneous safety needle sets, and precision flow rate tubing, which work together as integrated mechanical delivery solutions. The company serves healthcare providers, patients, and pharmaceutical partners in the United States and international markets, with applications across home care, emergency care, hospital settings, nursing homes, and other medical facilities. KORU Medical Systems Inc. plays a specialized role in the medical devices market by helping make subcutaneous infusion therapies more practical, patient-centric, and widely usable across different care environments.

CEO Mr. Adam Kalbermatten · 73 employees · United States · https://www.korumedical.com